Articles tagged with Cancer Medication
A new study published in PLOS ONE found that over 78% of US adults supported larger health warnings on cigarette packs, even among smokers. The researchers suggest that these findings support the implementation of larger pack warnings as required by the 2009 Tobacco Control Act.
Researchers developed a new method to design more effective breast cancer treatments by combining patient-derived xenografts and proteogenomic integration. This approach allows for the identification of potential targets for drugs and has shown promise in suppressing tumor growth in laboratory models.
Researchers analyzed proteins in breast tumors and found multiple protein targets that could respond to drugs, including PI3K inhibitors and mTOR inhibitors. The study also identified potential benefits for HER2 positive breast cancer patients if analysis of tumor proteins is taken into consideration.
Scientists at Northwestern University have developed a miniature female reproductive tract that can test new drugs for safety and effectiveness in women. The EVATAR system, made with human tissue, mimics the body's dynamics and will help understand diseases such as endometriosis, fibroids, and cancer.
A three-year research collaboration aims to create more accurate ways of measuring cancer progression. The project uses digital images from completed clinical trials to develop drug response metrics, with the goal of identifying optimal tumor burden measurement methods.
Researchers develop immunotherapy approach for prostate cancer by combining anti-hormonal drug with checkpoint inhibitors, driving T cells into tumors and blocking PD-L1/PD1 response. Targeting VISTA brake is also shown to inhibit immune response in human tumors.
Scientists at Sylvester Comprehensive Cancer Center have found that p300 protein acts as a tumor suppressor, preventing myelodysplastic syndrome (MDS) from developing into acute myeloid leukemia (AML). Eliminating p300 in mice results in rapid leukemia development.
A study published in Briefings in Functional Genomics investigates the role of epigenetics in cancer development, showing that disruptions can activate oncogenes or shut down tumor suppressors. The paper also highlights the link between epigenetic changes and metabolites, which can target and amplify gene expression.
Researchers at Mass General Hospital identified novel resistance mechanisms in patients with liver tumors receiving FGFR inhibitor treatment. The study found that different mutations within individual patients and across multiple samples could confer resistance, highlighting the need for more effective treatments.
A genome sequencing study for rare parathyroid carcinoma has identified mutations in known cancer-related genes and pathways, providing a clear view of genetic mechanisms involved. This in-depth characterization could lead to the first therapy options for patients with this deadly cancer.
Researchers developed a protocol to detect high-precision how, where, and why drugs interact with DNA biomolecules. This method uses X-ray radiation and advanced simulations to rationalize drug preferences, revealing new insights into the mechanism of platinum-based drugs like Pt103.
Researchers have found that pembrolizumab, an immunotherapy drug, can effectively treat malignant pleural mesothelioma, a disease primarily caused by asbestos inhalation. The study, led by Evan Alley, showed promising results with tumor reduction and improved overall survival in patients.
Researchers developed a new method to search for synthetic-lethal gene combinations using CRISPR/Cas9, uncovering 120 new opportunities for cancer drug development. The technique allowed them to test thousands of gene mutation combinations simultaneously, revealing more than 120 new synthetic-lethal interactions.
A new study by Penn researchers found that Medicare patients with chronic illnesses, such as cancer and rheumatoid arthritis, paid an average of $6,322 per year in out-of-pocket costs under Medicare Part D. The study proposes policy changes to cap annual out-of-pocket costs and spread them more evenly throughout the year.
The absence of protein SPRED2 alone can trigger excessive grooming behavior in mouse models. The study identifies the Ras/ERK-MAP kinase cascade as a key signaling pathway involved in obsessive-compulsive disorder (OCD). Administering an inhibitor to this pathway improves OCD symptoms, suggesting new potential treatments.
Researchers at the University of Bradford have developed a peptide that blocks RAN protein and kill cancer cells. The new treatment uses nanoparticles to deliver the peptide directly into cancer cells, showing promising results in lab tests.
Researchers developed a new drug delivery method using antibody-drug conjugates (ADCs) that show high precision and stability. The method successfully treated hard-to-treat solid and liquid tumors, including HER2 breast cancer and CD138 multiple myeloma, without harming healthy cells.
The ABC Global Alliance, led by ESO, has launched a call-to-action to improve and extend the lives of patients with advanced breast cancer by 2025. The initiative outlines key gaps and actionable imperatives across patient care, societal support, and scientific investment for mBC.
Three Harvard experts discuss the economics of precision medicine, highlighting factors such as innovative incentives, higher prices due to biologic drugs, and limited competition. The authors propose potential solutions to increase patient access to these medicines, including financial instruments and price competition.
Researchers develop CelePlum-777, a nanoparticle-based drug combo that kills melanoma cells with minimal side effects. The treatment reduces cancer cell growth and resists resistance development, offering new hope for melanoma patients.
A University of Leicester study found that folinic acid can protect neurons in fruit flies with Parkinson's disease, offering potential hope for people with early-onset forms of the condition. The researchers believe that supplementing folinic acid could be a faster and more effective treatment option than developing new drugs.
A phase 2 clinical trial of sacituzumab govitecan, an antibody-drug conjugate targeting Trop-2, achieved a response in 21 participants with advanced triple-negative breast cancer. The responses were early and durable, lasting up to 20 months, with improved overall survival.
Researchers discovered that many breast cancer patients have mutational signatures similar to those with faulty BRCA1 or BRCA2 genes, suggesting they may also benefit from existing PARP inhibitor treatments. This opens up the possibility of treating up to 20% of women with these drugs.
Scientists have designed two new drug candidates that target specific types of cancer by binding to defective RNAs. The compounds, called Targapremir-18a and Targapremir-210, successfully kill prostate and triple negative breast cancer cells without causing broader side effects.
Recent advances in understanding regulatory mechanisms of HH pathway and chemical regulation are discussed. CAS scientists propose a hypothetical model for endogenous chemical modulation and suggest precise interventions for better therapeutic outcomes.
Researchers at Mayo Clinic have identified a specific protein implicated in drug resistance, as well as a possible therapeutic tool. By engineering a peptide that blocks the activity of another protein ERK, the team found that it can prevent chemotherapy resistance and tumor growth.
Researchers have identified a class of enzymes that play an active role in regulating stress granules, which help cancer cells defend themselves against treatments. Disabling these enzymes can lower SG levels, opening doors to new therapeutics for various diseases.
A new study shows that even with PD-1 blockade, tumor-specific T cells require CD28 co-stimulation to expand and restore effective immune responses. This finding suggests that only a subset of tumor-specific CD8 T cells will proliferate after PD-1-directed therapy.
A nearly 11-year follow-up study published in the New England Journal of Medicine shows an estimated overall survival rate of 83.3% among 1,106 patients with chronic myeloid leukemia treated with Gleevec. The treatment has been proven effective against multiple forms of cancer, including pediatric CML and gastrointestinal stromal tumor.
Researchers at Scripps Research Institute have discovered a disordered protein, CITED2, that outcompetes another protein, HIF1α, for cellular binding targets. This finding has implications for future cancer drugs, suggesting a more efficient approach to interrupting cancer cell survival mode.
Cabozantinib activates neutrophils, the first-responders of the immune system, to infiltrate tumor cells and trigger an immune response that leads to complete clearance of invasive prostate cancers. This innovative approach could lead to novel combination cancer immunotherapies.
Researchers at UCI have identified a specific mutation that allows melanoma tumor cells to evade the immune system. This finding may lead to more effective immunotherapies and targeted treatments for patients with melanoma.
Researchers have identified a protein biomarker, CD151, expressed on tumour cells of high-grade serous ovarian cancer, which is linked to poor prognosis. The study provides new information about possible targets for ovarian cancer treatment and has the potential to develop a clinical screening tool.
Researchers in Florida have identified a possible association between cancer incidence rates and Superfund sites. The study found that counties with Superfund sites had a 6% higher rate of adult cancer cases, suggesting a link between toxic environmental waste and adverse health outcomes.
A study found that the drug everolimus protects ovaries from cyclophosphamide, a common chemotherapy used against breast cancer, which depletes egg cells needed to achieve pregnancy. Female mice treated with everolimus and chemotherapy had more than twice as many offspring as those treated with chemotherapy alone.
A recent study published in JAMA Oncology found that exercise alone and psychological interventions significantly reduced cancer-related fatigue. The research analyzed 113 studies involving over 11,000 patients and concluded that exercise is the most effective approach to alleviate this debilitating side effect of cancer treatment.
A meta-analysis of 113 randomized clinical trials found that exercise, psychological interventions, and their combination were effective in reducing cancer fatigue. Pharmaceutical interventions did not show the same magnitude of improvement.
Researchers at Beth Israel Deaconess Medical Center have discovered a vulnerability in triple-negative breast cancer cells that can be exploited by blocking pyrimidine production. This finding provides a new strategy to combat the disease, which currently has limited treatment options.
Researchers at Ohio State University Comprehensive Cancer Center have identified a mechanism by which cancer cells develop resistance to FGFR inhibitors. By inhibiting the regulatory protein Akt, they found that cell proliferation, migration, and invasion could be slowed in lung and bladder cancer cells.
A rheumatoid arthritis drug has been found to block a metabolic pathway that drives tumor growth in aggressive cancers with the PTEN gene mutation. Leflunomide kills human breast cancer cells in mice by damaging DNA produced through the pathway.
Breast cancer patients who receive nine-week Herceptin treatment experience significant increases in survival rates and quality-adjusted life-years. The study found that switching to the nine-week course could save the NHS over £100 million a year, while being just as effective as the current 12-month duration.
A new potential strategy has been discovered to personalize therapy for brain and blood cancers, targeting tumors lacking the protein PTEN. The approach combines two pharmaceutical-grade drugs to eliminate PTEN-deficient cancer cells, offering a promising new treatment option.
Researchers have identified a powerful new pathway for enhanced blood cancer therapies by combining epigenetic drugs with immune-based treatments. This approach has shown promising results in inducing cancer cell death and overcoming resistance.
Researchers at MIT have developed a machine that can rapidly produce large quantities of customized peptides in about 37 seconds. This technology could help researchers generate new peptide drugs to test on various diseases and also produces customized cancer vaccines for individual patients.
A combination of two cancer drugs has been found to inhibit both dengue and Ebola virus infections in mice, with efficacy also shown against West Nile and Zika viruses. The study identified a molecular mechanism by which the drugs disrupt RNA viruses' genetic material.
A new compound developed by the Deshaies group inhibits Rpn11 activity, causing massive accumulation of dysfunctional proteins in cancer cells. This leads to catastrophic stress and cell death, making it a promising alternative to existing cancer drugs.
The Detroit Research on Cancer Survivors (Detroit ROCS) study aims to better understand the major factors affecting cancer progression, recurrence, mortality and quality of life in African American cancer survivors. The five-year, $9 million study will include 5,560 cancer survivors to identify key risk factors and develop intervention...
Researchers at Michigan State University have shown that breast cancer treatment options can be predicted based on gene expression patterns. The study identified a three-drug combination effective in stopping triple-negative breast cancer growth and suggests a personalized approach to care.
Researchers at the University of Pittsburgh School of Medicine have identified a novel genetic mechanism and marker that may predict response to a class of drugs in many cancer types. Elevated levels of IGF2BP3 protein were found in both thyroid and other common cancers, suggesting its potential as a biomarker for treatment response.
A new study found that cancer survivors are changing their prescription drug use due to financial constraints, with a significant proportion of non-elderly adults skipping medication or seeking cheaper options. This phenomenon has important policy implications and highlights the need for improved doctor-patient communication about the ...
Research from the SWOG study shows that nearly one in four patients treated with Gleevec will survive 10 years, highlighting the importance of banked biospecimens to drive new scientific findings. The study also found significant survival rates for patients with specific KIT mutations.
Researchers at Cincinnati Children's Hospital Medical Center successfully treated patients with deadly, treatment-resistant blood cancers using gene-guided therapy. The targeted approach identified specific genes fueling the diseases and prescribed molecular drugs to put them into remission.
Researchers at the Children's Hospital of Eastern Ontario discovered a combination therapy amplifies kill rates of cancer tumour cells using SMAC Mimetics and immune checkpoint inhibitors. The treatment also promotes long-term immunity against glioblastoma tumours, showing high cure rates in mice.
Researchers developed a new tool to analyze genetic changes in ovarian cancer, revealing pathways disrupted by the loss and gain of genes. The study found that targeting autophagy genes showed promise in treating chemotherapy-resistant disease.
A randomized Phase II clinical trial demonstrated that ProLon targets the aging process, reducing risk factors for age-related diseases such as diabetes, cancer, and cardiovascular disease in humans. The study found significant reductions in body weight, BMI, total body fat, and inflammation, while increasing relative lean body mass.
A UMass Amherst study found that current incentives for developing orphan drugs are not sufficient to meet patients' needs, leading to unmet health needs and barriers to access. The researchers call for a comprehensive understanding of the ethical considerations of access to safe and effective orphan drugs.
A team of experts has developed a set of diagnostic criteria for idiopathic multicentric Castleman disease, a life-threatening condition often misdiagnosed as other illnesses. The new criteria will help doctors diagnose the disease more accurately, leading to timely treatment and improved patient outcomes.
Researchers at the University of British Columbia have developed a magnetic drug implant that can deliver precise doses of medication on demand. The device uses a magnet to trigger the release of drugs into surrounding tissue, offering a potential alternative to traditional pill or injection-based treatments.
Scientists at Scripps Research Institute have been awarded $3.3 million to create a new class of anti-cancer drugs called antibody-drug conjugates (ADCs). These ADCs target aggressive breast cancer types with high efficiency.
A registry study of over 72,000 styrene-exposed employees found no increased incidence of common cancers such as oesophagus or lung cancer. However, a possible increased risk of myeloid leukaemia and nasal cancer was detected, highlighting the need for further investigation.